Company intelligence / Profile preview
Cancuravax
Greenville, South Carolina, United Statescancuravax.com.au ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cancuravax was a clinical-stage biotechnology company that specialized in the development of personalized autologous cancer vaccines. The company's core technology involved the use of tumor lysate-particle loaded (TLPL) systems to present a broad spectrum of patient-specific tumor antigens to the immune system. Its lead programs targeted high-risk melanoma and other solid tumors, utilizing both dendritic cell-based and particle-only delivery methods. Cancuravax's research and clinical trials laid the groundwork for the TLPL platform currently being advanced by Orbis Health Solutions.
- Therapeutic areas
- Oncology
- Modalities
- VaccineBiologicCell therapyDendritic cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Cancuravax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cancuravax.